v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities    
Net loss $ (5,609,874) $ (2,089,208)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of original issue discount 80,541 183,857
Depreciation and amortization expense 1,043,586 558
Amortization of right of use asset 11,020
Unrealized loss on equity investment 4,000
Change in fair value of convertible notes payable 259,852
Gain on extinguishment of liabilities (68,920) (18,301)
Equity-based compensation 159,583
Allowance for doubtful accounts 199,000 (3,927)
Changes in operating assets and liabilities    
Accounts receivable 5,054
Accounts receivable – other (48,213)
Inventories 2,883 13,868
Prepaid expenses and other 53,632 127,027
Interest receivable (3,925) (41,293)
Accounts payable 724,472 (300,293)
Accrued compensation 155,585 29,878
Accrued creator commissions 128,948 45,155
Settlement payable (113,634) 108,166
Accrued expenses (208,627) 104,694
Accrued sales tax 36,302 20,861
Deferred revenue 38,718 503,491
Operating lease (4,918)
Net cash used in operating activities (3,115,776) (1,354,626)
Cash flows from investing activities    
Cash acquired through acquisition (Note 2) 591,686
Capitalized internally developed software (141,883)
Issuance of note receivable (900,000)
Net cash used in investing activities (141,883) (308,314)
Cash flows from financing activities    
Proceeds from debt, net of issuance costs 1,500,000
Repayment of debt (430,204)
Deferred offering costs 14,029 (8,328)
Issuance of common stock from Equity Line of Credit, net of issuance costs 381,447
Issuance of common stock from At-The-Market Offering, net of issuance costs 1,267,533
Proceeds from issuance of Series C preferred stock – net of issuance costs 499,935
Net cash provided by financing activities 1,232,805 1,991,607
Net increase (decrease) in cash (2,024,854) 328,667
Cash - beginning of period 2,874,710 155,647
Cash - end of period 849,856 484,314
Supplemental disclosure of non-cash investing and financing activities    
Series A preferred dividends converted to common stock 209,267
Right of use asset obtained in exchange for operating lease 153,875
Convertible notes converted to common stock 654,333
Acquisition through issuance of Series D and Merger Warrants 75,000,000
Accrued expenses converted to Series C and warrants 82,020
Forgiveness of note receivable and interest with note payable and interest from Acquisition 4,478,181
Accrued Series A dividends $ 18,600 $ 56,100